The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jan. 12, 2016

Filed:

Dec. 14, 2005
Applicants:

Christophe DE Romeuf, Lambersart, FR;

Christine Gaucher, Sequedin, FR;

Jean-luc Teillaud, Paris, FR;

Jean-françois Prost, Versailles, FR;

Inventors:

Christophe De Romeuf, Lambersart, FR;

Christine Gaucher, Sequedin, FR;

Jean-Luc Teillaud, Paris, FR;

Jean-François Prost, Versailles, FR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/30 (2006.01); A61K 39/395 (2006.01); C12N 5/12 (2006.01); C07K 16/28 (2006.01); A61K 51/10 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2896 (2013.01); A61K 51/1069 (2013.01); C07K 16/2887 (2013.01); C07K 16/3061 (2013.01); A61K 2039/505 (2013.01); C07K 2317/24 (2013.01); C07K 2317/56 (2013.01); C12N 2510/02 (2013.01);
Abstract

The invention is directed to a monoclonal antibody directed against CD20 antigen, for therapeutic administration to humans, wherein each of the light chains of the antibody is encoded by murine-human chimeric nucleic acid sequence SEQ ID No. 27, and each of the heavy chains of the antibody is encoded by murine-human chimeric nucleic acid sequence SEQ ID No. 19. The invention is further directed to methods of in vitro activation of FcγRIIIA receptors in immune effector cells with the antibody and methods of treating CD20-expressing leukaemia or lymphoma with the antibody.


Find Patent Forward Citations

Loading…